A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099
This study is recruiting at 10 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohn Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Om Research LLC · Oxnard, CA
Colorado · 1
- South Denver Gastroenterology · Englewood, CO
Florida · 2
- Gastro Health Research - Miami · Miami, FL
- Ezy Medical Research · Miami Lakes, FL
Georgia · 1
- Atlanta Gastroenterology Associates - Peachtree Dunwoody · Atlanta, GA
Kansas · 1
- Cotton O'Neil Digestive Health Center · Topeka, KS
Missouri · 1
- KAD Clinical Research · St Louis, MO
Nevada · 1
- Vector Clinical Trials · Las Vegas, NV
Texas · 2
- One of a Kind Clinical Research Center - Kingwood · Kingwood, TX
- Southern Star Research Institute · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.